Tomita Y - Search Results

1

mRNA and protein expression of p53 mutations in human bladder cancer cell lines.

Kawasaki T, Tomita Y, Watanabe R, Tanikawa T, Kumanishi T, Sato S. Kawasaki T, et al. Among authors: tomita y. Cancer Lett. 1994 Jul 15;82(1):113-21. doi: 10.1016/0304-3835(94)90154-6. Cancer Lett. 1994. PMID: 8033064

2

Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma.

Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y. Saito T, et al. Among authors: tomita y. Br J Cancer. 1996 Feb;73(3):327-31. doi: 10.1038/bjc.1996.57. Br J Cancer. 1996. PMID: 8562338 Free PMC article.

3

Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder.

Wakatsuki S, Watanabe R, Saito K, Saito T, Katagiri A, Sato S, Tomita Y. Wakatsuki S, et al. Among authors: tomita y. Cancer Lett. 1996 May 15;103(1):11-7. doi: 10.1016/0304-3835(96)04194-8. Cancer Lett. 1996. PMID: 8616803

4

Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.

Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson KP, Wiman KG. Tomita Y, et al. Int J Cancer. 1996 May 3;66(3):322-5. doi: 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0. Int J Cancer. 1996. PMID: 8621251

5

Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations.

Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Kawasaki T, et al. Among authors: tomita y. Int J Cancer. 1996 Nov 15;68(4):501-5. doi: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7. Int J Cancer. 1996. PMID: 8945622

6

MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.

Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y. Saito T, et al. Among authors: tomita y. Cancer Lett. 1996 Dec 3;109(1-2):15-21. doi: 10.1016/s0304-3835(96)04395-9. Cancer Lett. 1996. Corrected and republished in: Cancer Lett. 1997 May 1;115(1):121-7. doi: 10.1016/s0304-3835(97)04754-x PMID: 9020898 Corrected and republished.

7

MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.

Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y. Saito T, et al. Among authors: tomita y. Cancer Lett. 1997 May 1;115(1):121-7. doi: 10.1016/s0304-3835(97)04754-x. Cancer Lett. 1997. PMID: 9097987

8

Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.

Bilim VN, Tomita Y, Kawasaki T, Takeda M, Takahashi K. Bilim VN, et al. Among authors: tomita y. Cancer Lett. 1998 Jun 5;128(1):87-92. doi: 10.1016/s0304-3835(98)00055-x. Cancer Lett. 1998. PMID: 9652797

9

Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).

Bilim VN, Kawasaki T, Takahashi K, Tomita Y. Bilim VN, et al. Among authors: tomita y. Anticancer Res. 1998 May-Jun;18(3A):1655-9. Anticancer Res. 1998. PMID: 9673385

10

Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.

Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K, Tomita Y. Bilim V, et al. Among authors: tomita y. Clin Cancer Res. 2000 Feb;6(2):460-6. Clin Cancer Res. 2000. PMID: 10690524

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,547 results

Search Page

Filters